Pediatrics. 2002 Jul;110(1 Pt 1):181-3.
New regulatory initiatives have been designed to ensure that new drugs and biologicals include adequate pediatric labeling for the claimed indications at the time of, or soon after, approval. However, because such labeling may not immediately be available, off-label use (or use that is not included in the approved label) of therapeutic agents is likely to remain common in the practice of pediatrics. This policy statement was written to address questions practitioners have regarding off-label use. The purpose of off-label use is to benefit the individual patient. Practitioners may use their professional judgment to determine these uses. Practitioners should understand that the Food and Drug Administration does not regulate off-label use.
新的监管举措旨在确保新药和生物制品在获批时或获批后不久,就其声称的适应症包含充分的儿科标签。然而,由于此类标签可能无法立即获得,治疗药物的非标签使用(即未包含在批准标签中的使用)在儿科实践中可能仍很常见。撰写本政策声明是为了解答从业者关于非标签使用的疑问。非标签使用的目的是使个体患者受益。从业者可运用其专业判断力来确定这些使用情况。从业者应明白,美国食品药品监督管理局并不监管非标签使用。